CovidChloroV1, Main, Corpus, bibRecord, 001207

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.

Identifieur interne : 001207 ( Main/Corpus ); précédent : 001206; suivant : 001208

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.

Auteurs : Tesia Bobrowski ; Lu Chen ; Richard T. Eastman ; Zina Itkin ; Paul Shinn ; Catherine Chen ; Hui Guo ; Wei Zheng ; Sam Michael ; Anton Simeonov ; Matthew D. Hall ; Alexey V. Zakharov ; Eugene N. Muratov

Source :

bioRxiv : the preprint server for biology ; 2020.

RBID : pubmed:32637956

Abstract

COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro . Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.

DOI: 10.1101/2020.06.29.178889
PubMed: 32637956
PubMed Central: PMC7337386

Links to Exploration step

pubmed:32637956

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.</title>
<author><name sortKey="Bobrowski, Tesia" sort="Bobrowski, Tesia" uniqKey="Bobrowski T" first="Tesia" last="Bobrowski">Tesia Bobrowski</name>
<affiliation><nlm:affiliation>Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Lu" sort="Chen, Lu" uniqKey="Chen L" first="Lu" last="Chen">Lu Chen</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Eastman, Richard T" sort="Eastman, Richard T" uniqKey="Eastman R" first="Richard T" last="Eastman">Richard T. Eastman</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Itkin, Zina" sort="Itkin, Zina" uniqKey="Itkin Z" first="Zina" last="Itkin">Zina Itkin</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shinn, Paul" sort="Shinn, Paul" uniqKey="Shinn P" first="Paul" last="Shinn">Paul Shinn</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Catherine" sort="Chen, Catherine" uniqKey="Chen C" first="Catherine" last="Chen">Catherine Chen</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guo, Hui" sort="Guo, Hui" uniqKey="Guo H" first="Hui" last="Guo">Hui Guo</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zheng, Wei" sort="Zheng, Wei" uniqKey="Zheng W" first="Wei" last="Zheng">Wei Zheng</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Michael, Sam" sort="Michael, Sam" uniqKey="Michael S" first="Sam" last="Michael">Sam Michael</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Simeonov, Anton" sort="Simeonov, Anton" uniqKey="Simeonov A" first="Anton" last="Simeonov">Anton Simeonov</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hall, Matthew D" sort="Hall, Matthew D" uniqKey="Hall M" first="Matthew D" last="Hall">Matthew D. Hall</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zakharov, Alexey V" sort="Zakharov, Alexey V" uniqKey="Zakharov A" first="Alexey V" last="Zakharov">Alexey V. Zakharov</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Muratov, Eugene N" sort="Muratov, Eugene N" uniqKey="Muratov E" first="Eugene N" last="Muratov">Eugene N. Muratov</name>
<affiliation><nlm:affiliation>Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32637956</idno>
<idno type="pmid">32637956</idno>
<idno type="doi">10.1101/2020.06.29.178889</idno>
<idno type="pmc">PMC7337386</idno>
<idno type="wicri:Area/Main/Corpus">001207</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001207</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.</title>
<author><name sortKey="Bobrowski, Tesia" sort="Bobrowski, Tesia" uniqKey="Bobrowski T" first="Tesia" last="Bobrowski">Tesia Bobrowski</name>
<affiliation><nlm:affiliation>Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Lu" sort="Chen, Lu" uniqKey="Chen L" first="Lu" last="Chen">Lu Chen</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Eastman, Richard T" sort="Eastman, Richard T" uniqKey="Eastman R" first="Richard T" last="Eastman">Richard T. Eastman</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Itkin, Zina" sort="Itkin, Zina" uniqKey="Itkin Z" first="Zina" last="Itkin">Zina Itkin</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shinn, Paul" sort="Shinn, Paul" uniqKey="Shinn P" first="Paul" last="Shinn">Paul Shinn</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Catherine" sort="Chen, Catherine" uniqKey="Chen C" first="Catherine" last="Chen">Catherine Chen</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guo, Hui" sort="Guo, Hui" uniqKey="Guo H" first="Hui" last="Guo">Hui Guo</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zheng, Wei" sort="Zheng, Wei" uniqKey="Zheng W" first="Wei" last="Zheng">Wei Zheng</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Michael, Sam" sort="Michael, Sam" uniqKey="Michael S" first="Sam" last="Michael">Sam Michael</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Simeonov, Anton" sort="Simeonov, Anton" uniqKey="Simeonov A" first="Anton" last="Simeonov">Anton Simeonov</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hall, Matthew D" sort="Hall, Matthew D" uniqKey="Hall M" first="Matthew D" last="Hall">Matthew D. Hall</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zakharov, Alexey V" sort="Zakharov, Alexey V" uniqKey="Zakharov A" first="Alexey V" last="Zakharov">Alexey V. Zakharov</name>
<affiliation><nlm:affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Muratov, Eugene N" sort="Muratov, Eugene N" uniqKey="Muratov E" first="Eugene N" last="Muratov">Eugene N. Muratov</name>
<affiliation><nlm:affiliation>Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">bioRxiv : the preprint server for biology</title>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using <i>in silico</i>
 approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them <i>in vitro</i>
 . Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32637956</PMID>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Jun</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>bioRxiv : the preprint server for biology</Title>
<ISOAbbreviation>bioRxiv</ISOAbbreviation>
</Journal>
<ArticleTitle>Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">2020.06.29.178889</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1101/2020.06.29.178889</ELocationID>
<Abstract><AbstractText>COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using <i>in silico</i>
 approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them <i>in vitro</i>
 . Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bobrowski</LastName>
<ForeName>Tesia</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eastman</LastName>
<ForeName>Richard T</ForeName>
<Initials>RT</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Itkin</LastName>
<ForeName>Zina</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shinn</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Guo</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Michael</LastName>
<ForeName>Sam</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Simeonov</LastName>
<ForeName>Anton</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hall</LastName>
<ForeName>Matthew D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zakharov</LastName>
<ForeName>Alexey V</ForeName>
<Initials>AV</Initials>
<AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Maryland 20850, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Muratov</LastName>
<ForeName>Eugene N</ForeName>
<Initials>EN</Initials>
<AffiliationInfo><Affiliation>Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>OT3 TR002020</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 CA207160</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>bioRxiv</MedlineTA>
<NlmUniqueID>101680187</NlmUniqueID>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Mol Ther. 2020 Dec 14;:</RefSource>
<PMID Version="1">33333292</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32637956</ArticleId>
<ArticleId IdType="doi">10.1101/2020.06.29.178889</ArticleId>
<ArticleId IdType="pmc">PMC7337386</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2013 Apr;57(4):1743-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23357765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mem Inst Oswaldo Cruz. 2020 Feb 27;115:e190357</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32130369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Inform. 2012 Apr;31(3-4):202-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27477092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Rev. 2006 Sep;58(3):621-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Liver. 1992 Aug;12(4 Pt 1):183-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1406082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2004 Nov;64(2):127-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15498608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2014 Jul;107:84-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24769245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Jun 23;64(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32366720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Clin Pharmacol Ther. 2002 May;40(5):213-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12051573</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2010 Jul 26;50(7):1189-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20572635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2009 Feb 20;284(8):5229-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19106108</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2016;21(7):595-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27035622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2016 Feb;21(2):225-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26360051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2010 Jul 1;202(1):65-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20486856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Mar 4;350(10):1023-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14999114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1051-1056</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32149769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Aug;73(8):6862-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10400784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Cent Sci. 2020 May 27;6(5):672-683</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32483554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014;58(4):1943-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24419340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2019 Dec;24(12):2341-2349</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31585169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2020 Jul;165(7):1517-1526</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32322993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Ther. 2020 May 6;14(2):107-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32321878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Soc Rev. 2020 Jun 7;49(11):3525-3564</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2016 Jul 25;56(7):1243-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27280890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioinformatics. 2019 Dec 15;35(24):5382-5384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31410449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>iScience. 2019 Sep 27;19:1279-1290</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31402258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Pharm. 2016 Feb 1;13(2):545-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26669717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Chem Biol. 2020 Jul;16(7):791-800</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1993 Mar;37(3):540-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8384816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2020 Mar;19(3):149-150</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32127666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2018 Feb 26;58(2):212-218</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29300482</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):227-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27095301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2019 Jun 17;10(1):2674</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31209238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2006 Nov;72(2):157-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16797734</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16381955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Inform. 2010 Jul 12;29(6-7):476-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27463326</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2003 Apr;58(2):159-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12742576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Aug 23;8(8):e72791</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24009705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2019 Dec 23;59(12):4968-4973</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31769676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Transl Sci. 2019 Mar;12(2):91-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30412340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Chem Biol. 2015 Aug;11(8):535</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26196763</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biosyst. 2016 Feb;12(2):614-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26687590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2016 Oct;22(10):1101-1107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27571349</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2014 Jun 26;57(12):4977-5010</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24351051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biopharm Drug Dispos. 2008 Sep;29(6):324-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18570280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2008 Apr 10;51(7):2062-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18324764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2002 Oct;56(1):61-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12323400</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17005807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res Perspect. 2015 Jun;3(3):e00149</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26171228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2019 Nov 25;59(11):4613-4624</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31584270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Oct;100(1):215-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23981392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):106020</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32405156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 May 28;181(5):1036-1045.e9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2008;15(10):997-1005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18393857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Pharmacol. 1987;33(4):409-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3327698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2017 Jan;137:165-172</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27890675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Sep;73(9):7641-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10438855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Apr 8;369:m1432</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32269046</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Jul;583(7816):459-468</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32353859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2018 Jun 5;4:31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29872540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Graph Model. 2002 Jan;20(4):269-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11858635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Dec;7(12):864-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19881520</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001207 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001207 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32637956
   |texte=   Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32637956" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki